Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALGS

ALGS - Aligos Therapeutics Inc Stock Price, Fair Value and News

$7.54+0.13 (+1.75%)
Market Closed

42/100

ALGS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

42/100

ALGS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALGS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALGS Price Action

Last 7 days

8.0%

Last 30 days

1.1%

Last 90 days

-43.3%

Trailing 12 Months

-26.6%

ALGS RSI Chart

ALGS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALGS Valuation

Market Cap

46.6M

Price/Earnings (Trailing)

-1.93

Price/Sales (Trailing)

21.31

EV/EBITDA

-1.22

Price/Free Cashflow

-0.56

ALGS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALGS Fundamentals

ALGS Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

-78.35%

Rev. Growth (Qtr)

-77.19%

ALGS Earnings

Earnings (TTM)

-24.2M

Earnings Growth (Yr)

75.8%

Earnings Growth (Qtr)

36.96%

ALGS Profitability

EBT Margin

-1092.36%

Return on Equity

-45.18%

Return on Assets

-27.33%

Free Cashflow Yield

-177.11%

ALGS Investor Care

Shares Dilution (1Y)

59.87%

Diluted EPS (TTM)

-5.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025797.0K1.3M1.7M2.2M
20247.4M5.9M5.0M334.0K
202312.8M11.6M10.5M9.3M
20226.0M8.2M10.7M13.9M
20210004.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Aligos Therapeutics Inc

ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEaligos.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES68

Aligos Therapeutics Inc Frequently Asked Questions

ALGS is the stock ticker symbol of Aligos Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Aligos Therapeutics Inc is 46.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, ALGS's PE ratio (Price to Earnings) is -1.93 and Price to Sales (PS) ratio is 21.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALGS PE ratio will change depending on the future growth rate expectations of investors.